SCHEMBL2401968

SCHEMBL2401968

Cc1nc(N)c(Br)cc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.46
HPGD P15428 2/20 0.42
ALDH1A1 P00352 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
HTT P42858 3/20 0.39
KMT2A Q03164 1/20 0.39
NQO2 P16083 1/20 0.39
BACE1 P56817 1/20 0.33
TERT O14746 1/20 0.33
NQO1 P15559 1/20 0.32
PRNP P04156 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
NOD2 Q9HC29 1/20 0.31
NOS1 P29475 3/20 0.31
NOS3 P29474 2/20 0.31
NOS2 P35228 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CYP3A4 P08684 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29693601 1.00 LMNA (0.46) LMNAHPGDALDH1A1APOBEC3GHTT
SCHEMBL7002357 0.83 LMNA (0.44) LMNAHPGDALDH1A1APOBEC3GHTT
SCHEMBL30037705 0.83 LMNA (0.44) LMNAHPGDALDH1A1APOBEC3GHTT
SCHEMBL29693617 0.83 LMNA (0.44) LMNAHPGDALDH1A1APOBEC3GHTT
SCHEMBL6635851 0.83 LMNA (0.44) LMNAHPGDALDH1A1APOBEC3GHTT
SCHEMBL16666040 0.83 LMNA (0.44) LMNAHPGDALDH1A1APOBEC3GHTT
SCHEMBL1565399 0.83 LMNA (0.44) LMNAHPGDALDH1A1APOBEC3GHTT
SCHEMBL2258481 0.81 NQO2 (0.46) LMNAHPGDALDH1A1APOBEC3GHTT
SCHEMBL18951964 0.79 LMNA (0.41) LMNAHPGDALDH1A1APOBEC3GHTT
SCHEMBL15537882 0.79 LMNA (0.41) LMNAHPGDALDH1A1APOBEC3GHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118047654-A Process for preparing aryl halides starting from aromatic amines 黑龙江立科新材料有限公司 2024-05-17 CN disclosed
US-11935803-B2 Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2024-03-19 US disclosed
CN-116134029-A Oxo-nitrogen ring derivative regulator, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-05-16 CN disclosed
EP-3372601-B1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2022-09-21 EP disclosed
WO-2022121914-A1 OXO-NITROGEN RING DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海翰森生物医药科技有限公司 2022-06-16 WO disclosed
WO-2022121914-A1 OXO-NITROGEN RING DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 上海翰森生物医药科技有限公司 2022-06-16 WO disclosed
CN-112004845-B Resin composition, laminate, semiconductor wafer with resin composition layer, substrate, and semiconductor device 三菱瓦斯化学株式会社 2022-05-31 CN disclosed
US-20210277221-A1 RESIN COMPOSITION, LAMINATE, SEMICONDUCTOR WAFER WITH RESIN COMPOSITION LAYER, SUBSTRATE FOR MOUNTING SEMICONDUCTOR WITH RESIN COMPOSITION LAYER AND SEMICONDUCTOR DEVICE MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2021-09-09 US disclosed
EP-3786200-A1 RESIN COMPOSITION, LAMINATE, RESIN COMPOSITION LAYER-ATTACHED SEMICONDUCTOR WAFER, SUBSTRATE FOR MOUNTING RESIN COMPOSITION LAYER-ATTACHED SEMICONDUCTOR, AND SEMICONDUCTOR DEVICE MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2021-03-03 EP disclosed
CN-112004845-A Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer, and semiconductor device 三菱瓦斯化学株式会社 2020-11-27 CN disclosed
US-20050192310-A1 Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 BRISTOL-MYERS SQUIBB COMPANY 2005-09-01 US disclosed
US-20050176723-A1 (Halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents MERCK SHARP & DOHME CORP. 2005-08-11 US disclosed
EP-1515727-A2 (HALO-BENZO CARBONYL)HETEROBICYCLIC P38 KINASE INHIBITING AGENTS Merck & Co., Inc. (US) 2005-03-23 EP disclosed
US-6849642-B2 Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring GRUENENTHAL GMBH (DE) 2005-02-01 US disclosed
WO-2003103590-A2 (HALO-BENZO CARBONYL)HETEROBICYCLIC P38 KINASE INHIBITING AGENTS MERCK & CO., INC. (US) 2003-12-18 WO disclosed
US-20020183327-A1 Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring GRUENENTHAL GMBH. 2002-12-05 US disclosed
EP-0750620-A4 CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT MERCK & CO INC (US) 1997-07-16 EP disclosed
EP-0750620-A1 CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT MERCK & CO. INC. (US) 1997-01-02 EP disclosed
US-5496816-A Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment MERCK & CO., INC. (US) 1996-03-05 US disclosed
WO-1995025108-A1 CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 1995-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183327-A1 Bicyclic imidazo-3-yl-amine derivatives substituted on the 6-membered ring OPRK1, GRIN3A, OPRM1 LMNA 2073/4885HPGD 1448/4885ALDH1A1 974/4885
US-20050192310-A1 Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 HSD17B3, HSD17B1, HSD17B2 LMNA 2571/4885HPGD 31/4885ALDH1A1 317/4885
US-20050176723-A1 (Halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents UACA, MAPK1, MAPKAPK2 LMNA 4372/4885HPGD 973/4885ALDH1A1 1686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.